Zura Bio Ltd Ordinary Shares - Class A 94E
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- €3.40
- Day Range
- €3.42–3.42
- 52-Week Range
- €1.73–34.86
- Bid/Ask
- €3.46 / €3.56
- Market Cap
- €217.80 Mil
- Volume/Avg
- 0 / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Zura Bio Ltd is a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 15
- Website
- https://www.zurabio.com
Comparables
Valuation
|
Metric
|
94E
|
GHRS
|
EQRX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.62 | 2.97 | 0.97 |
Price/Sales | — | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
94E
GHRS
EQRX
Financial Strength
|
Metric
|
94E
|
GHRS
|
EQRX
|
|---|---|---|---|
Quick Ratio | 6.12 | 21.70 | 18.43 |
Current Ratio | 6.17 | 22.06 | 18.78 |
Interest Coverage | — | −108.75 | — |
Quick Ratio
94E
GHRS
EQRX
Profitability
|
Metric
|
94E
|
GHRS
|
EQRX
|
|---|---|---|---|
Return on Assets (Normalized) | −53.80% | −13.14% | −15.72% |
Return on Equity (Normalized) | −87.06% | −13.56% | −16.71% |
Return on Invested Capital (Normalized) | −66.21% | −17.81% | −21.31% |
Return on Assets
94E
GHRS
EQRX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Hdvnfkgzwt | Lpx | $635.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Phvyrcgr | Pwhzbc | $124.1 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Xzffbwn | Kcmgfk | $114.2 Bil | |||
| Moderna Inc
MRNA
| Xyytttw | Dfnj | $53.7 Bil | |||
| argenx SE ADR
ARGX
| Ndwyjrxph | Ljrcm | $23.0 Bil | |||
| BioNTech SE ADR
BNTX
| Fhgvhsl | Dvrbs | $22.2 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Htbfgbgw | Xvwdchq | $20.3 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Lfhqqqqb | Bnxcyt | $15.9 Bil | |||
| United Therapeutics Corp
UTHR
| Tffzsjbs | Xkkb | $12.8 Bil | |||
| Incyte Corp
INCY
| Tkhzhhsfv | Fchqnm | $12.2 Bil |